|Bid||50.00 x 800|
|Ask||71.61 x 800|
|Day's Range||71.17 - 71.89|
|52 Week Range||51.12 - 74.42|
|Beta (5Y Monthly)||-0.02|
|PE Ratio (TTM)||41.31|
|Forward Dividend & Yield||0.33 (0.48%)|
|Ex-Dividend Date||Jul 10, 2020|
|1y Target Est||80.78|
Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet Avigan®/Reeqonus™, a drug being used in several countries to treat patients with mild to moderate cases of COVID-19.
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).